Sanofi plans to dominate the MS market. Bill Sibold, who heads up the MS unit which is part of the Genzyme subsidiary, told Reuters that the plan is to bring in-house products to the market as well as through acquisitions.
Sibold answered Reuters’s question about whether or not acquisitions would be limited by a price tag by saying the firm is “well resourced to execute our strategy.”
Sanofi attempted to bolster its MS lineup with IV medication Lemtrada (alemtuzumab) to go with the oral Aubagio (teriflunomide), but the FDA rejected Lemtrada in December, and Reuters notes that new orals, like Novartis’s Gilenya (fingolimod) and Biogen Idec’s Tecfidera (dimethyl fumarate) have really taken hold of the marketplace, displacing injectables.
